Generics Janssen has historically had a very strong focus on emerging markets. In today’s world, where growth for the pharmaceutical industry overwhelmingly comes from emerging markets, where do we find the Nordics? What is the relevance of the Nordics for the country’s global footprint? Jansen has preserved the cluster model. We…
Bavarian Nordic If there is one thing that successful Danish companies have in common with one another, it is the clear recognition of abundant opportunities outside the motherland. “Danish companies’ strengths lie in their ability to build on what they have inherited from Denmark but to also look outward and be…
Denmark “The Nordic region—the ‘quiet North’ as it could have been called—counterbalances the turbulence in Southern Europe,” says Zinta Krumins, managing director Nordics, Boehringer Ingelheim, when asked about the relevance of the Nordics to the company. “The Nordics is a very stable region, with small but reasonable growth prospects, very good…
Nordic Drugs Could you begin by giving a short introduction to Nordic Drugs and its current position within the structure of owner Nordic Group? Nordic Drugs started as a 100% owned subsidiary of Ferring in January 1995. Several years later, in 1998, we were divested out from Ferring. Today we are owned…
diabetes Carlos Manuel González Parra discusses the progress Novo Nordisk has made as a newcomer to the Colombian market and its hopes and intentions for the future. One of the main focuses is in manoeuvring Novo Nordisk Colombia into a position where they will be a key player in the diabetes…
Gilead Nordics As the blockbuster sales model fades, the rush is on for a new formula for growth, termed ‘Good growth’ by Pharmaceutical Executive: niched, balanced & sustainable with high margins from protected pricing, more patient-friendly than patent-centric and with revenues coming from a deep reservoir of unmet medical need. How well…
Baltic You refer to AstraZeneca as the locomotive of bioscience in Sweden. Can you elaborate on what you mean by that, and the role that you see for AstraZeneca in pushing this development forward? AstraZeneca has a significant R&D presence in Sweden. We currently have more than 2,300 researchers at our…
Nordic Last year, Boston Scientific took important steps to stabilise and strengthen its core businesses. Could you develop on the development trajectory of Boston Scientific in the Nordic region so far? I have only been with the company for a year now, but what happened is that Boston Scientific have acquired…
Nordics Mary Di Marzio has been General Manager of Nordics for Shire Inc for nearly 2 years now. Today she shares with Pharmaboardroom the progress of Shire’s relatively new branch in Scandinavia. She continues to give insights into the balancing act between pricing versus reimbursement and how they are raising awareness…
Novo Nordisk - Ireland Novo Nordisk is primarily known as the premier global diabetes player—so let us begin by examining the realities of diabetes in Ireland. In 2012, the International Diabetes Federation estimated that there were 191,380 people with diabetes in Ireland—6.1% of the population—and that by 2030, the number would rise to 278,850.…
Novo Nordisk - Australia Can you start by commenting on the state of diabetes in Australia at present? According to 2011 statistics nearly one million Australians have diabetes and about half of those are not aware that they have the condition. Australia is ranked 7th in the world in terms of prevalence of type…
Novo Nordisk - Belgium Looking into your background, we see that you have developed your career in the local industry’s top 3 players: Pfizer, AstraZeneca and Novartis until assuming your position as General Manager of Novo Nordisk BeLux less than a year ago. What motivated you to join the company back in 2010 and…
See our Cookie Privacy Policy Here
